OPTHEA LTD (F:UKJ) — Market Cap & Net Worth
Market Cap & Net Worth: OPTHEA LTD (UKJ)
OPTHEA LTD (F:UKJ) has a market capitalization of $11.99 Million (€10.26 Million) as of June 17, 2026. Listed on the F stock exchange, this Germany-based company holds position #26597 globally and #2292 in its home market, demonstrating a -25.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OPTHEA LTD's stock price €0.01 by its total outstanding shares 1367978173 (1.37 Billion). Review OPTHEA LTD debt and liabilities to assess the company's total debt and financial obligations.
OPTHEA LTD Market Cap History: 2017 to 2026
OPTHEA LTD's market capitalization history from 2017 to 2026. Data shows change from $714.89 Million to $11.99 Million (-39.28% CAGR).
OPTHEA LTD Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OPTHEA LTD's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
20471.17x
OPTHEA LTD's market cap is 20471.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $879.62 Million | $90.68K | -$92.82 Million | 9699.95x | N/A |
| 2023 | $514.98 Million | $108.00K | -$142.52 Million | 4768.31x | N/A |
| 2024 | $745.28 Million | $125.00K | -$220.24 Million | 5962.23x | N/A |
| 2025 | $511.78 Million | $25.00K | -$162.79 Million | 20471.17x | N/A |
Competitor Companies of UKJ by Market Capitalization
Companies near OPTHEA LTD in the global market cap rankings as of June 17, 2026.
Key companies related to OPTHEA LTD by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
OPTHEA LTD Historical Marketcap From 2017 to 2026
Between 2017 and today, OPTHEA LTD's market cap moved from $714.89 Million to $ 11.99 Million, with a yearly change of -39.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €11.99 Million | -97.66% |
| 2025 | €511.78 Million | -31.33% |
| 2024 | €745.28 Million | +44.72% |
| 2023 | €514.98 Million | -41.45% |
| 2022 | €879.62 Million | -23.08% |
| 2021 | €1.14 Billion | -35.00% |
| 2020 | €1.76 Billion | -41.49% |
| 2019 | €3.01 Billion | +469.70% |
| 2018 | €527.77 Million | -26.17% |
| 2017 | €714.89 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of OPTHEA LTD was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.99 Million USD |
| MoneyControl | $11.99 Million USD |
| MarketWatch | $11.99 Million USD |
| marketcap.company | $11.99 Million USD |
| Reuters | $11.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OPTHEA LTD
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).… Read more